Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pelthos Therapeutics Inc. (PTHS)
USD27.20
+1.80 (+7.09%)
US AMEX Healthcare Biotechnology
Address
4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 27703
Durham, NC, US
Durham, NC, US
CEO
Scott Plesha
Website
pelthos.com
IPO
2025-07-02
CIK 1919246 ISIN US1711262048
Description
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD27.20
+1.80 (+7.09%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
20.4K
Beta
3.20
Float Shares
133.7K
Free Float %
20.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.50% | +5.61% | +16.07% | +46.89% | -19.76% | -13.81% | +126.44% | +126.44% | +126.44% | +126.44% | +126.44% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
27.20
Low
50.00
+83.8%
Consensus
57.75
+112.3%
Median
57.50
+111.4%
High
66.00
+142.6%
DCF (Unlevered)
86.04
+216.3%
DCF (Levered)
29.17
+7.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
66.00
+142.6%
|
| Last Quarter | 2 |
60.50
+122.4%
|
| Last Year | 7 |
56.86
+109.0%
|
| All Time | 7 |
56.86
+109.0%
|
Quality scores
Altman Z-Score
-1.07
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-70.2% Q1'26: +3.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-189.7% Q1'26: -122.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-193.1% Q1'26: -120.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-58.2% Q1'26: -93.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+220.0% Q1'26: +440.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.16× Q1'26: -1.15× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 2 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
16.80M
est: 16.59M (+1.2%)
|
63.68M
62.19M – 65.58M
+283.8% YoY
|
117.55M
111.33M – 123.66M
+84.6% YoY
|
170.26M
167.21M – 173.31M
+44.8% YoY
|
206.60M
189.66M – 240.41M
+21.3% YoY
|
244.79M
224.73M – 284.86M
+18.5% YoY
|
| EBITDA |
-30.07M
est: 9.96M (-402.1%)
|
38.21M
37.31M – 39.35M
+283.8% YoY
|
70.53M
66.80M – 74.20M
+84.6% YoY
|
102.16M
100.33M – 103.99M
+44.8% YoY
|
123.96M
113.80M – 144.25M
+21.3% YoY
|
146.87M
134.84M – 170.92M
+18.5% YoY
|
| EBIT |
-32.43M
est: 9.96M (-425.7%)
|
38.21M
37.31M – 39.35M
+283.8% YoY
|
70.53M
66.80M – 74.20M
+84.6% YoY
|
102.16M
100.33M – 103.99M
+44.8% YoY
|
123.96M
113.80M – 144.25M
+21.3% YoY
|
146.87M
134.84M – 170.92M
+18.5% YoY
|
| Net Income |
-43.32M
est: -28.67M (-51.1%)
|
-19.15M
-24.68M – -13.62M
+33.2% YoY
|
-2.75M
-5.92M – 408.9K
+85.6% YoY
|
6.01M
3.14M – 8.88M
+318.3% YoY
|
9.39M
8.39M – 11.39M
+56.3% YoY
|
13.75M
12.29M – 16.68M
+46.4% YoY
|
| SGA |
41.72M
est: 21.52M (+93.9%)
|
82.58M
80.65M – 85.05M
+283.8% YoY
|
152.45M
144.38M – 160.38M
+84.6% YoY
|
220.81M
216.85M – 224.76M
+44.8% YoY
|
267.93M
245.97M – 311.78M
+21.3% YoY
|
317.46M
291.44M – 369.42M
+18.5% YoY
|
| EPS |
-23.04
est: -15.98 (-44.2%)
|
-10.35
-13.12 – -7.24
+35.2% YoY
|
-1.67
-3.15 – 0.22
+83.9% YoY
|
3.44
1.67 – 4.72
+306.5% YoY
|
5.00
4.46 – 6.06
+45.1% YoY
|
7.31
6.53 – 8.87
+46.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-15 | Oppenheimer | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.68M
OE per share TTM
-3.22
Owner's Yield
-12.07%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
75.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
17
Total invested
19.17M
Insider transactions (90d)
1
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
17
+2 vs prev Q
New positions
5
Closed positions
3
Increased
13
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MURCHINSON LTD. | 296.3K +6.8K (+2.4%) | 6.23M -2.7M (-30.6%) | 8.95% -0.229 pp | 0.79% -0.657 pp | USD27.93 -24.8% | 3 qtrs — |
| 2 | IKARIAN CAPITAL, LLC | 256.6K +840.0 (+0.3%) | 5.39M -2.5M (-32.0%) | 7.75% -0.360 pp | 0.44% -0.181 pp | USD30.24 -30.5% | 3 qtrs — |
| 3 | — | 93.1K +93.1K (+100.0%) | 1.96M +2.0M (+100.0%) | 2.81% +2.811 pp | 0.00% +0.000 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 4 | BOOTHBAY FUND MANAGEMENT, LLC | 81.9K +1.2K (+1.5%) | 1.72M -781.2K (-31.2%) | 2.47% -0.086 pp | 0.02% -0.015 pp | USD30.08 -30.2% | 3 qtrs — |
| 5 | J. GOLDMAN & CO LP | 50.4K -27.6K (-35.4%) | 1.06M -1.4M (-56.2%) | 1.52% -0.951 pp | 0.03% -0.033 pp | USD31.00 -32.2% | 2 qtrs — |
| 6 | CANTOR FITZGERALD, L. P. | 41.4K +6.4K (+18.4%) | 870.3K -214.4K (-19.8%) | 1.25% +0.142 pp | 0.01% -0.004 pp | USD29.45 -28.7% | 2 qtrs — |
| 7 | KNOTT DAVID M JR | 21.1K +1.8K (+9.3%) | 442.7K -155.0K (-25.9%) | 0.64% +0.025 pp | 0.26% -0.013 pp | USD29.28 -28.2% | 3 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 15.3K +1.7K (+12.2%) | 321.2K -101.1K (-23.9%) | 0.46% +0.030 pp | 0.00% +0.000 pp | USD27.89 -24.7% | 3 qtrs — |
| 9 | PALE FIRE CAPITAL SE | 12.9K +4.8K (+59.5%) | 271.4K +20.3K (+8.1%) | 0.39% +0.133 pp | 0.02% +0.007 pp | USD27.27 -23.0% | 2 qtrs — |
| 10 | VANGUARD FIDUCIARY TRUST CO | 9.8K +9.8K (+100.0%) | 206.3K +206.3K (+100.0%) | 0.30% +0.296 pp | 0.00% +0.000 pp | USD21.01 +0.0% | 1 qtrs NEW |
| 11 | PERSISTENT ASSET PARTNERS LTD | 6.0K +— (+0.0%) | 126.2K -60.0K (-32.2%) | 0.18% -0.009 pp | 0.05% -0.037 pp | USD29.80 -29.5% | 3 qtrs — |
| 12 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 1.9K +— (+0.0%) | 40.1K -19.1K (-32.2%) | 0.06% -0.003 pp | 0.00% 0.000 pp | USD28.00 -25.0% | 3 qtrs — |
| 13 | UBS GROUP AG | 764.00 +330.0 (+76.0%) | 16.1K +2.6K (+19.3%) | 0.02% +0.009 pp | 0.00% +0.000 pp | USD26.15 -19.7% | 3 qtrs — |
| 14 | FARTHER FINANCE ADVISORS, LLC | 40.00 +40.0 (+100.0%) | 852.00 +852.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD21.00 +0.0% | 1 qtrs NEW |
| 15 | ASPECT PARTNERS, LLC | 16.00 +16.0 (+100.0%) | 336.00 +336.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD21.00 +0.0% | 1 qtrs NEW |
| 16 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 21.00 +21.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD21.00 +0.0% | 3 qtrs — |
| 17 | MILLENNIUM MANAGEMENT LLC | — -11.1K (-100.0%) | — -342.8K (-100.0%) | 0.00% -0.351 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 132.5K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 417.3K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.4K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 12.0K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 887.54 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.05M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.5K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.4K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 989.85 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 109.09 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | GAY JOHN M. | Officer | — | — | Stock Option | 93,000 | 13.50 | 1.26M | 0 | D | ↗ |
| 2026-04-10 | GAY JOHN M. | Officer | — | — | Common Stock | 0 | 0.00 | — | 30,518 | D | ↗ |
| 2026-04-02 | Pauls Matthew | Director | S-Sale | D | Common Stock | 371 | 21.36 | 7.9K | 15,150 | D | ↗ |
| 2026-04-02 | Malamut Richard | Director | S-Sale | D | Common Stock | 280 | 21.36 | 6.0K | 27,422 | D | ↗ |
| 2026-04-02 | Greenleaf Peter | Director | S-Sale | D | Common Stock | 377 | 21.36 | 8.1K | 24,681 | D | ↗ |
| 2026-04-02 | Friedberg Ezra M | Director | S-Sale | D | Common Stock | 265 | 21.36 | 5.7K | 82,027 | D | ↗ |
| 2025-12-23 | Einhorn Andrew J. | Director | A-Award | A | Common Stock | 12,000 | 0.00 | 1.20 | 12,000 | D | ↗ |
| 2025-12-17 | LIGAND PHARMACEUTICALS INC | Director / 10% Owner | A-Award | A | Senior Secured Convertible Note | 0 | 29.73 | — | 0 | D | ↗ |
| 2025-12-10 | Pauls Matthew | Director | G-Gift | D | Common Stock | 9,542 | 0.00 | — | 1,074 | D | ↗ |
| 2025-11-25 | Friedberg Ezra M | Director | S-Sale | D | Common Stock | 1 | 28.50 | 28.50 | 32,000 | I | ↗ |
| 2025-11-13 | Malamut Richard | Director | A-Award | A | Common Stock | 2,454 | 0.00 | — | 8,904 | D | ↗ |
| 2025-11-06 | LIGAND PHARMACEUTICALS INC | Director / 10% Owner | A-Award | A | Senior Secured Convertible Note | 0 | 34.44 | — | 0 | D | ↗ |
| 2025-10-02 | Pauls Matthew | Director | M-Exempt | A | Common Stock | 2,123 | 0.00 | — | 10,616 | D | ↗ |
| 2025-07-02 | Rangarao Sai | Officer | A-Award | A | Common Stock | 30,518 | 0.00 | — | 30,518 | D | ↗ |
| 2025-07-02 | Plesha Scott M. | Director / Officer | A-Award | A | Stock Option | 255,000 | 13.50 | 3.44M | 255,000 | D | ↗ |
| 2025-07-02 | Pauls Matthew | Director | M-Exempt | A | Common Stock | 8,493 | 0.00 | — | 8,493 | D | ↗ |
| 2025-07-02 | Malamut Richard | Director | A-Award | A | Stock Option | 58,230 | 13.50 | 786.1K | 58,230 | D | ↗ |
| 2025-07-02 | Greenleaf Peter | Director | A-Award | A | Common Stock | 25,478 | 0.00 | — | 25,478 | D | ↗ |
| 2025-07-02 | Friedberg Ezra M | Director | A-Award | A | Restricted Stock Units | 19,108 | 13.50 | 258.0K | 28,012 | D | ↗ |
| 2025-07-02 | Francis Knuettel II | Officer | A-Award | A | Common Stock | 33,472 | 0.00 | — | 33,472 | D | ↗ |
| 2025-07-02 | Davis Todd C | Director | A-Award | A | Restricted Stock Units | 19,108 | 13.50 | 258.0K | 36,969 | D | ↗ |
| 2025-07-02 | Baxter Richard B | Director | A-Award | A | Common Stock | 19,108 | 0.00 | — | 19,108 | D | ↗ |
| 2025-07-01 | Pauls Matthew | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-01 | LIGAND PHARMACEUTICALS INC | 10% Owner | C-Conversion | A | Common Stock | 1,500,000 | 10.00 | 15.00M | 1,500,000 | D | ↗ |
| 2025-07-01 | Greenleaf Peter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-01 | Friedberg Ezra M | Director | C-Conversion | D | Series A Convertible Preferred Stock | 40,000 | 10.00 | 400.0K | 0 | I | ↗ |
| 2025-07-01 | Francis Knuettel II | Officer | J-Other | A | Series A Convertible Preferred Stock | 10,000 | 10.00 | 100.0K | 10,000 | I | ↗ |
| 2025-07-01 | Davis Todd C | Director / 10% Owner | J-Other | A | Series A Convertible Preferred Stock | 31,279 | 10.00 | 312.8K | 3,127,868 | I | ↗ |
| 2025-07-01 | Baxter Richard B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-13 | Friedberg Ezra M | Director | A-Award | A | Common Stock | 2,454 | 0.00 | — | 63,477 | D | ↗ |
| 2024-11-13 | Davis Todd C | Director | A-Award | A | Common Stock | 4,961 | 0.00 | — | 20,778 | D | ↗ |
| 2024-06-14 | Malamut Richard | Director | A-Award | A | Common Stock | 6,450 | 0.00 | — | 6,450 | D | ↗ |
| 2024-06-14 | Friedberg Ezra M | Director | A-Award | A | Common Stock | 6,450 | 0.00 | — | 61,023 | D | ↗ |
| 2024-06-14 | Davis Todd C | Director | A-Award | A | Common Stock | 12,900 | 0.00 | — | 15,817 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-8.11M
Shares Outstanding
648.5K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Francis Knuettel | CFO, Treasurer & Secretary | 744.2K | male |
| John Gay | CFO, Treasurer & Secretary | 744.2K | male |
| Scott Plesha | Chief Executive Officer, President & Director | 685.7K | male |
| Sai Rangarao | Chief Commercial Officer | 579.4K | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PTHS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
